Bladder Cancer

The phase 2 DESTINY-PanTumor02 trial included patients with HER2-expressing solid tumors such as bladder, pancreatic and rare tumors.

Bladder cancer survivors face a bevy of challenges post-treatment, but an immediately available service strives to ease the burden.

Important data may encourage gender-specific treatment making decisions for patients with bladder cancer.

The addition of Tecentriq to platinum-based chemotherapy/gemcitabine did not boost outcomes in patients with metastatic bladder cancer, according to results from the IMvigor 140 trial.

Researchers identified several biomarkers that may indicate how a patient responds to Padcev, a type of antibody drug conjugate for patients with urothelial carcinoma, a type of bladder cancer.

A clinical trial just kicked off, analyzing Padcev in patients with advanced, unresectable bladder cancer.

Data suggests an association between tumor DNA circulating in plasma and patient responses to neoadjuvant treatment.

From funding updates on the Cancer Moonshot to Howie Rose’s bladder cancer diagnosis and more, here’s what’s happening in the oncology space this week.

The first patient was dosed with lerapolturev in a phase 1/2 clinical trial evaluating the drug in patients with bladder cancer and other solid tumors.

Cancer — and its treatments — can feel like a grueling race, but I’m using frequent follow-ups and an excellent care team to stay ahead of the game.

The Food and Drug Administration is speeding up the review and potential approval of Padcev plus Keytruda for certain patients with urothelial carcinoma, the most common form of bladder cancer.

Patients with non-muscle invasive bladder cancer who currently smoke or previously smoked should consider quitting to possibly improve health outcomes in survivorship, according to an expert.

Adstiladrin represents the first gene therapy approved by the FDA for the treatment of patients with high-risk non-muscle invasive bladder cancer who are resistant to BCG, the first-line standard of care for these patients.

Patients with non-muscle invasive bladder cancer who smoke should consider quitting to possibly improve health outcomes in survivorship, according to an expert.

Sexual dysfunction is not less common in women with bladder cancer who undergo reproductive organ-sparing radical cystectomy, although more research is needed.

Men often decide to tough out their cancer alone, but tough guy Terry Bradshaw is starting to open up about his sometimes-rocky journey with the disease.

From a childhood cancer survivor throwing out the first pitch at Game 4 of the World Series to former WWE champion and actor Dwayne “The Rock” Johnson recording a message for a child with brain cancer, here’s what’s happening in the cancer space this week.

Talking about the end of life can be difficult, but these conversations are crucial for patients with incurable cancer to have with their clinicians, experts say.

From the death of standup comedian and "Love Goddess" Judy Tenuta to professional sports hall-of-famers discussing their cancer, here’s what’s happening in the cancer space this week.

Long-term outcomes from this trial confirm the benefit of treatment with chemoradiotherapy over chemotherapy alone for patients with muscle-invasive bladder cancer.

The phase 3 MAGNOLIA trial will assess whether abelacimab can prevent venous thromboembolism recurrence in patients with gastrointestinal or genitourinary cancers.

More than half of patients with metastatic, cisplatin-ineligible bladder cancer saw their cancer shrink when given Padcev and Keytruda in a clinical trial.

The FDA granted abelacimab a fast track designation for the treatment of thrombosis, a common and sometimes deadly type of blood clot associated with cancer.

Backed by her personal cancer experience, an oncology nurse became a volunteer with the Bladder Cancer Advocacy Network.

The study the FDA allowed to continue is investigating the safety and efficacy of the novel cancer drug ACR-368 in patients with endometrial, urothelial and ovarian cancer.

While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

The primary objective of the early-stage trial is to determine the maximum tolerated dose of the novel drug in a group of patients with recurrent and/or refractory solid tumors.

Treatment with a combination of Ofev and chemotherapy was shown to have a survival benefit in a group of patients with bladder cancer.

Once a recommended dose of the drug is determined, the study investigators will review the efficacy and safety associated with this treatment across a variety of patients with bladder and liver cancer, as well other solid tumors.